TY - JOUR
T1 - Nivolumab in renal cell carcinoma
T2 - Latest evidence and clinical potential
AU - Mazza, Camille
AU - Escudier, Bernard
AU - Albiges, Laurence
N1 - Publisher Copyright:
© SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses.
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Similar to melanoma, renal cell carcinoma (RCC) has been historically considered as an immunogenic tumor, with interleukin 2 (IL-2) and interferon alpha (IFN-α) being the first approved treatments in the 1990s. However, these therapies were effective in only 10-20% of cases and were not well tolerated. Recently, new insights on the interaction between the immune system and tumor have identified the programmed death-1/programmed death-ligand-1 (PD-1/PD-L1) pathway to be a key player in evading host immune responses. The strategy of immune checkpoint blockade is to reduce inhibitory signaling and restore the patient's natural tumor-specific T-cell-mediated immune responses. Nivolumab is the first PD-1 inhibitor to have gained approval for the treatment of patients with metastatic melanoma, squamous and nonsquamous non-small cell lung cancer (NSCLC), Hodgkin disease and recently RCC. In this review, we discuss results from studies of nivolumab in RCC, clinical experience with this agent, and its future development.
AB - Similar to melanoma, renal cell carcinoma (RCC) has been historically considered as an immunogenic tumor, with interleukin 2 (IL-2) and interferon alpha (IFN-α) being the first approved treatments in the 1990s. However, these therapies were effective in only 10-20% of cases and were not well tolerated. Recently, new insights on the interaction between the immune system and tumor have identified the programmed death-1/programmed death-ligand-1 (PD-1/PD-L1) pathway to be a key player in evading host immune responses. The strategy of immune checkpoint blockade is to reduce inhibitory signaling and restore the patient's natural tumor-specific T-cell-mediated immune responses. Nivolumab is the first PD-1 inhibitor to have gained approval for the treatment of patients with metastatic melanoma, squamous and nonsquamous non-small cell lung cancer (NSCLC), Hodgkin disease and recently RCC. In this review, we discuss results from studies of nivolumab in RCC, clinical experience with this agent, and its future development.
KW - immune checkpoint inhibitor
KW - immunotherapy
KW - nivolumab
KW - programmed death-1
KW - renal cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85014547529&partnerID=8YFLogxK
U2 - 10.1177/1758834016679942
DO - 10.1177/1758834016679942
M3 - Review article
AN - SCOPUS:85014547529
SN - 1758-8340
VL - 9
SP - 171
EP - 181
JO - Therapeutic Advances in Medical Oncology
JF - Therapeutic Advances in Medical Oncology
IS - 3
ER -